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Previous studies documented the ability of quinazoline-based a1-adrenoceptor antagonists to induce apoptosis in prostate cancer
cells via an a1-adrenoceptor-independent mechanism. In this study we investigated the molecular events initiating this apoptotic
effect. Since transforming growth factor-b1 (TGF-b1) mediates prostate epithelial cell apoptosis, we hypothesised that the activation
of the TGF-b1 pathway underlies the quinazoline-based apoptotic effect in prostate cancer cells. Treatment of the androgen-
independent human prostate cancer cells PC-3 with doxazosin resulted in a strong caspase-3 activation within 24h, whereas
tamsulosin, a sulphonamide-based a1-adrenoceptor antagonist, had no significant apoptotic effect against prostate cancer cells. To
identify the molecular components involved in this quinazoline-mediated apoptosis, cDNA microarray analysis of PC-3 prostate
cancer cells treated with doxazosin (3h) was performed. Induced expression of several genes was observed including p21
WAF-1 and
IkBa (inhibitor of NF-kB alpha). Relative quantitative reverse transcription–polymerase chain reaction analysis revealed induction of
several TGF-b1 signalling effectors: Induction of mRNA for Smad4 and the TGF-b1-regulated apoptosis-inducing transcription factor
TGF-b1-inducible early gene (TIEG1) was detected within the first 6h of doxazosin treatment. Upregulation of IkBa at both the
mRNA and protein level was also detected after 6h of treatment. Furthermore, doxazosin resulted in a considerable elevation in
Smad4 and TIEG protein expression (6h). A ‘latent’ increase in TGF-b mRNA expression was detected after 48h of treatment.
These findings suggest that the quinazoline-based doxazosin mediates prostate cancer apoptosis by initially inducing the expression of
TGF-b1 signalling effectors and subsequently IkBa. The present study provides an initial insight into the molecular targets of the
apoptotic action of quinazolines against prostate cancer cells.
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Prostate cancer continues to afflict many thousands of American
males and is the cause of approximately 30000 deaths per year
(Greenlee et al, 2000). Although therapeutic modalities such as
androgen ablation and radical prostatectomy are considered
curative for localised disease, no treatment for metastatic prostate
cancer is available, which shows a significant increase in length of
life (Raghavan, 1988; Crawford et al, 1989; Catalona et al, 1993).
The therapeutic significance of apoptosis in the treatment of
prostate cancer emerges from evidence suggesting that like normal
prostate epithelial cells, prostate cancer cells maintain sensitivity
to androgens and undergo apoptosis in response to androgen
withdrawal (Isaacs, 1994; Boyle, 2000). Androgen-independent
prostate cancer cells still contain the apoptotic machinery and can
undergo apoptosis in response to hormone-independent ap-
proaches (Bruckheimer and Kyprianou, 2000). Reactivation of cell
death pathways in prostate cancer cells represents a powerful
approach for pharmacological intervention, and consequently
targeting the apoptotic signalling in prostate cells has been the
focus of numerous investigations (Bruckheimer and Kyprianou,
2000).
A class of pharmacological agents, the a1-adrenoceptor antago-
nists, originally used as antihypertensive agents (Young and
Brogden, 1988), have been safely used as standard medical therapy
for benign prostatic hyperplasia (BPH) and the long-term relief of
lower urinary tract symptoms (LUTS) (Caine, 1988; Kirby, 1996).
Growing evidence suggests that two of these clinically used
a1-adrenoceptor antagonists, doxazosin and terazosin, that share
a similar chemical structure, the quinazoline nucleus (Figure 1),
exert a potent apoptotic effect against prostate cancer cells
(Kyprianou and Benning, 2000), via an a1-adrenoceptor-indepen-
dent mechanism (Benning and Kyprianou, 2002) and suppression
of tumour vascularity (Keledjian et al, 2001).
Apoptosis induction by androgen withdrawal in normal and
hormone-dependent malignant prostate involves the transforming
growth factor-b1 (TGF-b1) signalling pathway (Kyprianou and
Isaacs, 1989). Recent immunohistochemical analysis of BPH tissue
revealed an increase in TGF-b1 expression but no change in TGF-
bII receptor (TbRII) in patients who had undergone treatment
with the clinically used quinazoline-based a1-adrenoceptor an-
tagonist terazosin (Glassman et al, 2001). The TGF-b1 signalling
system normally functions to inhibit proliferation and induce
apoptosis of epithelial and endothelial cells (Massague et al, 2000);
its signal transduction pathway involves the receptor-mediated
activation by phosphorylation of the intracellular effectors, Smad2,
Smad3 and Smad4, and their translocation to the nucleus where
they regulate gene transcription (Massague, 2000). Expression and Revised 6 March 2003; accepted 12 March 2003
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sactivation of these intracellular effectors of the TGF-b1 pathway
are critical to the execution of the apoptotic process (DeCaestecker
et al, 2000). An inhibitory regulator of TGF-b1 signalling, Smad7,
(Whitman, 1997) is regulated by TGF-b1 specifically via Smad3
and Smad4 indicating a negative feedback mechanism (Hayashi
et al, 1997). Smad7 is induced during apoptosis of prostate
epithelial cells (Brodin et al, 1999) and has recently been shown to
sensitise other cell types to apoptosis (Mazars et al, 2001; Schiffer
et al, 2001).
The TGF-b1-inducible early gene (TIEG1) is another factor that
induces apoptosis in breast, lung and kidney cells (Tachibana et al,
1997; Chalaux et al, 1999; Hefferan et al, 2000), potentially by
downregulating the antiapoptotic protein bcl-2 (Chalaux et al,
1999).
This study aimed to identify the molecular mechanism under-
lying the apoptotic action of quinazoline-based a1-adrenoceptor
antagonists against prostate cancer cells. Our findings demonstrate
that doxazosin induces the apoptotic signalling potentially via the
activation of TGF-b1 pathway with a potential involvement of NF-
kB nuclear effectors.
MATERIALS AND METHODS
Materials
The a1-adrenoceptor antagonists used in this study were
generously provided by the following pharmaceutical companies:
doxazosin (Cardura; Doxazosin Mesylate) was provided by Pfizer
Pharmaceuticals (New York, NY, USA); terazosin (Hytrin;
terazosin hydrochloride) was obtained from Abbott Laboratories
(Abbot Park, IL, USA); and tamsulosin (Flomax) was provided by
Yamanouchi Pharmaceuticals (Tokyo, Japan).
Cell culture
The human prostate cancer PC-3 cell line was obtained from the
American Type Tissue Culture Collection (Rockville, MD, USA).
PC-3 cells were routinely maintained in RPMI (Life Technologies,
Gaithersburg, MD, USA), containing fetal bovine serum (FBS)
(10%) and antibiotics.
cDNA microarray analysis
Microarray analyses were performed according to the manufac-
turer’s instructions. Microarray filters (SuperArray Inc., Bethesda,
MD, USA) consisting of 23 markers for specific signal transduction
pathways including mitogenic (Egr-1, c-fos), antiproliferative (p19,
p21
Waf1) and p53 (mdm2, bax) pathways were used. Briefly, total
RNA was isolated from both untreated PC-3 cells (control) or cells
treated with doxazosin (25mM) for 3h. Biotin-labelled probes were
made from the isolated control and test RNA. The filters were
exposed to film and the genes were visualised as dots. A score for
the relative intensities of these genes was calculated after
densitometric analysis using the Scion Image program (National
Institutes of Health, USA, http://rsb.info.nih.gov/scion-image/).
Equal probe hybridisation to each filter was confirmed by b-actin
and GAPDH internal controls. Results represent the mean of two
independent experiments.
RT–PCR analysis
Exponentially growing cultures of PC-3 cells were treated with
doxazosin (25mM) for 6, 12, 24 and 48h. Total cellular RNA was
isolated from untreated control and treated cells using the Trizol
reagent. RNA (1mg) was reverse transcribed into cDNA using the
SuperScript II system (GIBCO BRL, Grand Island, NY, USA) in a
thermocycler (Biometra, Go ¨ttingen, Germany). The RNA, dNTPs
and random hexamers were incubated for 5min at 651C followed
by the addition of the buffer, reverse transcriptase (RT), Rnase
inhibitor and MgCl2, and the reaction mixture was incubated at
421C for 50min. The polymerase chain reaction for TGFb,T bRII,
Smad4, Smad7 and TIEG was performed in a total volume of 25ml
containing 0.5ml RT reaction mixture, 50mM KCl, 10mM Tris-HCl,
2m M MgCl2, 2.5U Taq DNA polymerase, 0.15mM of each forward
and reverse primer, and distilled water. The following cycling
conditions were used for 37 cycles in a thermal cycler (Perkin-
Elmer Gene Amp 2400 Wellesley, MA, USA or Biometra T
Gradient, Gottingen, Germany): initial denaturation, 5min at
941C; denaturation 30s at 941C; annealing 30s at 551C and
elongation, 30s at 721C. The programme was followed by a final
elongation step for 5min at 721C. Control reactions were
performed for each series by omitting either the mRNA or RT.
For qualitative analysis, RT–PCR products were electrophoresed
through agarose gels (2.5%) and visualised with ethidium bromide
staining.
Relative quantitative RT–PCR was performed with the Quan-
tumRNA
TM 18S Internal Standards kit (Ambion Austin, TX, USA)
according to the protocol recommended by the manufacturer with
some modifications. Briefly, the ratio of 18S rRNA primers to
competimers that resulted in a PCR product approximately equal
to abundance of the specific gene at the selected number of cycles
of amplification was determined. The recommended 18S primer:
competimer ratios of 1:9, 2:8 and 3:7 were tested and a 1:9 ratio
resulted in an approximately equal ratio for all four products.
Relative quantitative RT–PCR was subsequently performed using
RNA from untreated control and doxazosin-treated cells. Samples
(10ml) of PCR products were subjected to electrophoretic analysis
on agarose gels (1.8% wv
 1) and bands were visualised with SYBR
Gold nucleic acid stain (Molecular Probes, Eugene, OR, USA).
Densitometric analysis was performed using a UVP Bioimaging
System (Upland, CA, USA). The expression profile of the various
genes after doxazosin treatment was analysed in three independent
experiments.
Western blot analysis
Cells from untreated control and treated cells (with either
doxazosin or tamsulosin) were lysed in RIPA buffer (150mM
NaCl, 50mM Tris pH 8.0, 0.5% deoxycholic acid: 1% Nonidet P40
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Figure 1 Chemical structure of a1-adrenoceptor anatagonists. The
quinazoline nucleus is shared by the two quinazoline-based a1-adreno-
ceptor antagonists doxazosin and terazosin, but not by the methoxysul-
phonamide-derived a1-adrenoceptor antagonist tamsulosin.
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swith 1mM PMSF). Total cell lysates (30–50mg) were subjected to
sodium dodecyl sulphate (SDS)–polyacrylamide gel electrophor-
esis, then transferred onto Hybond-P membranes (Amersham
Pharmacia Biotech., Piscataway, NJ, USA). Membranes were
blocked with 5% dry milk in TBS-T (Tris-buffered-saline contain-
ing 0.05% Tween-20) for 1h at room temperature, and were
subsequently incubated with the primary antibody (18h at 41C).
Expression of specific proteins was assessed using the respective
antibodies: Smad4 (Oncogene, Boston, MA, USA), caspase-3
(Pharmigen, San Diego, CA, USA), IkBa (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), TIEG1 (a generous gift from Dr R
Urrutia, Mayo Clinic, Rochester, MN, USA) and a-actin was from
Calbiochem #CP01; San Diego, CA, USA). Following incubation
with the respective primary antibody, membranes were incubated
with species-specific horseradish peroxidase (HRP)-labelled sec-
ondary antibodies (1h at room temperature). Membranes were
subsequently incubated with the enhanced chemiluminescence
system (ECL, Amersham Life Sciences RPN 2108) and autoradio-
graphed using X-ray film (Amersham Pharmacia Biotech).
Densitometric analysis was performed using the Scion Image
Program (National Institutes of Health, USA, http://rsb.info.nih.-
gov/scion-image). Bands were normalised to a-actin expression
and shown as fold changes relative to untreated controls.
ELISA
The procedure was essentially performed according to the
manufacturer’s instructions (Promega, WI, USA). Briefly, a 96-
well plate was coated with TGF-b1 antibody in carbonate coating
buffer and incubated overnight at 41C. Supernatants derived from
PC-3 cells after various periods of doxazosin treatment were added
to the respective wells (0, 3, 6, 9 and 24h). Secondary anti-TGF-b1
(1:1000 dilution) was added to the samples and incubated for 2h.
Plates were subsequently washed and TGF-b1–horseradish
peroxidase (HRP) conjugate was added. Upon termination of the
reaction, the absorbance was read at A450.
RESULTS
Previous studies have demonstrated that the piperizidinyl
quinazoline-based a1-adrenoceptor antagonists doxazosin and
terazosin (Figure 1) induce apoptosis in prostate cancer cells,
whereas the methoxysulphonamide-derived a1-adrenoceptor an-
tagonist tamsulosin had no apoptotic function (Kyprianou and
Benning, 2000). Caspases as apoptosis executioners upon sequen-
tial activation can cleave protein substrates leading to apoptotic
cell death (Cohen, 1997). To determine the involvement of the
caspase cascade in a1-adrenoceptor antagonist-mediated apoptosis
and the observed differences in apoptotic capability between these
two structurally dissimilar drugs, we investigated the activation of
caspase-3 in prostate cancer cells treated with either doxazosin or
tamsulosin. Western blotting revealed the temporal induction of
caspase-3 (17kDa) in doxazosin-treated cells after 9h, an effect
that was maintained up to 24h (Figure 2A). The activated form of
caspase-3 was not detected in tamsulosin-treated prostate cancer
cells (Figure 2B), consistent with the inability of this compound to
induce apoptosis (Kyprianou and Benning, 2000).
In order to determine the early alterations in gene expression
that may be causally involved in quinazoline-induced apoptosis,
cDNA microarray analyses were performed. RNA was isolated
from cultures of PC-3 cells, untreated control or following
treatment with doxazosin (25mM) for 3h. Table 1 summarises
the expression profile of doxazosin-regulated genes in human
prostate cancer cells. Out of the 23 genes examined, eight were
upregulated by at least two-fold, whereas four were downregulated.
Our array analysis revealed a dramatic induction of two genes
within 3h of doxazosin treatment p21 (seven-fold) and IkBa (nine-
fold). Interestingly, both these genes are inducible by TGF-b1
(DeCaestecker et al, 2000; Massague, 2000), suggesting a potential
reactivation of this signalling pathway by doxazosin. Two other
apoptosis-regulating genes were also moderately induced, the fas
ligand (43-fold) and hsf1 (four-fold).
Since induced expression of IkBa was detected within 3h of
doxazosin treatment (Table 1), we examined the mRNA and
protein expression profile in PC-3 cells over a 48-h treatment
period with the drug. The RT–PCR analysis revealed a significant
doxazosin-mediated induction in mRNA expression within 6h
(approx. 100% relative to untreated control cells); a maximum
increase in IkBa mRNA levels was detected after 24h and at 48h of
treatment a moderate decrease was observed (Figure 3A). A
parallel temporal elevation of IkBa protein expression reaching a
maximum after 24h of doxazosin treatment was detected by
Western blot analysis (Figure 4A).
To gain a further insight into the mechanism underlying
quinazoline-induced apoptosis, the temporal expression of several
genes involved in TGF-b1-mediated apoptosis, that is, the ligand
   -Actin
Procaspase-3
Caspase-3
0 3 6 9 12 24 0 3 6 9 12 24
Doxazosin (25 M) Tamsulosin (25 M)
32 kDa
17 kDa
Time (h)
42 kDa
A B
Figure 2 Effect of doxazosin on caspase-3 activation in prostate cancer
cells. PC-3 prostate cancer cells were cultured and treated with either
doxazosin (25mM) or tamsulosin (25mM) for 0, 3, 6, 9, 12 and 24h. Cell
lysates (40mg protein) were subjected to Western blotting as described in
‘Materials and Methods’. The expression and activation of caspase-3 in
response to doxazosin (panel A) and tamsulosin (panel B) treatment is
shown. Molecular weight sizes are indicated on the right.
Table 1 Microarray analysis of doxazosin-mediated gene expression in
prostate cancer cells
Gene Genebank ID Relative gene expression
ATF-2 (creb-2) X15875 0.1
Bax L22474 0.6
CD5 X04391 1.3
c-fos V01512 0.5
c-myc J00120 1.8
Cyp19 (aromatase p450) M28420 0.1
Egr-1 X52541 0.4
Fas ligand U08137 3.3
Gadd45 M60974 1.3
Hsf-1 (tcf5) M64673 4.4
Hsp27 (hsp b1) Z23090 1.6
Hsp90 (CDw52) X15183 1.7
ijBa (mad3) M69043 8.9
IL-2 U25676 1.9
iNOS L09210 0.6
Mdm2 Z12020 2.1
NFk B M58603 3.2
p19 U40343 2.5
p21
WAF-1 L47233 7.2
p53 M14694 NA
p57 (Kip2) U22398 1.2
NA¼not applicable. PC-3 cells were treated with doxazosin (25mM) for 3h and
subjected to microarray analysis as described in ‘Experimental Procedures’. Data
represent the mean scores of duplicate genes on each membrane from two
independent experiments. Values are expressed as the relative number of doxazosin-
treated vs untreated (control) cells. Bold characters indicate significant changes in
gene expression.
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Figure 3 Quantitative RT–PCR analysis of mRNA expression for TGF-b1 signalling pathway effectors in response to doxazosin. PC-3 prostate cancer
cells were treated with doxazosin (25mM) for 6, 12, 24 and 48h. Total RNA was isolated from untreated control and doxazosin-treated cells and subjected
to RT–PCR with primers specific for IkBa (panel A), TGFb (panel B), TIEG 1 (panel C), Smad4 (panel D), Smad7 (panel E), and relative quantitative RT–
PCR was performed as described in ‘Materials and Methods’. This figure is the representative of three independent experiments. The molecular weights for
the specific gene and the 18S products are shown on the right. The marker was a 1kb plus DNA ladder (GIBCO BRL).
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sTGF-b, its critical receptor TbRII receptor, the intracellular
effectors Smad4 and Smad7, and the nuclear factor TIEG1 was
evaluated. Since increased TGF-b1 protein expression is associated
with apoptosis (Glassman et al, 2001), we first examined the
expression profile of TGF-b1 in doxazosin-treated prostate cancer
cells. A significant increase in TGF-b1 mRNA expression were
detected within the first 12h of doxazosin treatment (Figure 3B).
This mRNA induction for TGF-b resulted in a significant increase
in the levels of active TGF-b1 protein produced by PC-3 prostate
cancer cells (Po0.05). After 24h of exposure to doxazosin, there
was a decline in TGF-b1 levels to baseline values (Figure 5). No
changes in the TbRII receptor mRNA expression by PC-3 cells
were observed in response to doxazosin (data not shown).
A marked induction in TIEG1 (Figure 3C) and Smad4
(Figure 3D) mRNA levels was observed within 6h of treatment
(65% increase), while there was a transient decrease in Smad7
mRNA expression for 24h of doxazosin exposure, and it was
subsequently followed by an upregulation by 48h compared to the
untreated control PC-3 cells (Figure 3E). Smad4 is an important
regulator of TGF-b1 signalling and apoptosis in a variety of cell
lines (Kim et al, 1996; Liu et al, 1997). Considering that Smad4
mRNA is upregulated, we investigated the effect of doxazosin on
Smad4 protein levels. As shown in Figure 4C, there was an increase
in Smad4 protein expression in response to doxazosin and this
elevation was maintained throughout all treatment periods
examined (up to 24h), a pattern that temporally correlates with
the mRNA expression profile (Figure 3D).
DISCUSSION
The ability of quinazoline-derived a1-adrenoceptor antagonists to
induce apoptosis in human prostate cancer cells via an a1-
adrenoceptor-independent mechanism has been established (Ky-
prianou and Benning, 2000; Benning and Kyprianou, 2002). The
present study focused on dissecting the molecular mechanism
underlying this action. Our findings demonstrate that caspase-3
was activated in response to doxazosin and not tamsulosin,
evidence confirming the apoptotic nature of the action of
quinazoline-derived a1-adrenoceptor antagonists against prostate
cell growth. This induction was first evident within 9h of treatment
and was maintained up to 24h, a pattern that temporally correlates
TIEG1
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Figure 4 Effect of doxazosin on IkBa, TIEG1 and Smad4 protein expression in prostate cancer cells. PC-3 prostate cancer cells were cultured and treated
with doxazosin (25mM) for times as indicated (0–24h). Cell lysates were isolated from treated and untreated cells and subjected to Western blot analysis.
Protein expression of IkBa (A), TIEG1 (B) and Smad4 (C) were examined by Western blotting using the respective antibodies as described in ‘Materials and
Methods’. Expression of a-actin was used as a normalising control and fold changes for each specific protein relative to untreated controls (after
normalisation to a-actin expression) are shown.
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Figure 5 Effect of doxazosin on TGF-b1 protein secretion by prostate
cancer cells. PC-3 prostate cancer cells were treated with doxazosin
(25mM) for various periods of time as indicated (0–24h). Supernatants
were obtained from treated cells and subjected to ELISA as described
under ‘Materials and Methods’. Values represent the mean of three
independent experiments performed in duplicate7standard deviation
(s.d.).
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swith the morphological manifestations of apoptosis in prostate
cancer cells following doxazosin treatment (Kyprianou and
Benning, 2000).
TGF-b1 has recently been shown to activate caspase-3 to induce
apoptosis in the NRP-154 prostate epithelial cell line (Chipuk et al,
2001), evidence supporting our hypothesis that doxazosin may
activate apoptosis of prostate cancer cells through TGF-b1
signalling. Doxazosin resulted in a ‘latent’ induction of TGF-b1
mRNA expression that was subsequent to a moderate increase in
the active TGF-b1 levels by prostate cancer cells PC-3 (after 24h of
treatment). While a similar pattern has been exhibited by
apoptotic T-cells with an enhanced release of active TGF-b1
without major changes in the mRNA expression (Chen et al, 2001),
one may also consider the possibility that the observed upregula-
tion of TGF-b mRNA in prostate cancer cells could be a
consequence of doxazosin-induced apoptosis. The lack of induc-
tion of TbRII expression in prostate cancer cells by doxazosin is
consistent with our earlier report indicating no changes in TbRII
protein levels in prostate tissue (from BPH patients) after
treatment with the quinazolines (Glassman et al, 2001). It appears
that doxazosin modulated the expression of the intracellular
effectors TGF-b1 signalling pathway, Smad4 and Smad7 proteins,
towards activation of the apoptotic machinery.
Microarray-based examination of doxazosin mediated-gene
expression revealed the rapid upregulation of two TGF-b1-
modulated genes, IkBa and p21
WAF-1. Doxazosin-induced over-
expression of IkBa may have implications for NF-kB intracellular
signalling. For instance, in prostate cancer cells and metastatic
melanoma cells, the blockade of NF-kB by a nondegradable
dominant-negative IkBa mutant suppresses angiogenesis, invasion
and metastasis (Huang et al, 2000, 2001), and may reduce the
apoptotic effects associated with NF-kB signalling (Baldwin, 1996).
These reports together with the observed upregulation of IkBa in
prostate cancer cells may provide a mechanism to explain the
increased apoptosis and reduced tumour vascularity in prostate
cancer specimens (Keledjian et al, 2001). Constitutive activation of
NF-kB has been reported in many tumours (Baldwin, 1996),
including androgen-independent prostate cancer cells (Pajonk
et al, 1999; Palayoor et al, 1999; Suh et al, 2002) and oestrogen
receptor-negative breast cancer cells (Biswas et al, 2001). This
activation of NF-kB survival signalling is believed to provide a
growth advantage in androgen-independent prostate cancer cells
by suppressing apoptosis and inducing cell adhesion and
angiogenic potential (Huang et al, 2001; Gasparian et al, 2002).
Smad4 is the principal intracellular effector of TGF-b1 signalling
and its expression is regulated at the protein and mRNA level by
doxazosin in PC-3 cells. The mechanism may involve the
inhibition of Smad4 degradation, recently reported to be mediated
by the oncogenic Ras pathway. Blockade of the oncogenic Ras
pathway using a quinazoline-based tyrosine kinase inhibitor (TKI)
PD98059 restores Smad4 expression levels and TGF-b1 signalling
in vitro (Saha et al, 2001). Upregulation of Smad4 would also
facilitate the transcription of several TGF-b1-regulated genes such
as Smad7 (Von Gersdorff et al, 2000). While Smad7 is induced
during androgen-withdrawal-induced apoptosis in prostate cells
(Brodin et al, 1999), Smad7 induction has also been shown to
antagonise directly TGF-b1 signalling (Whitman, 1997). Consider-
ing the evidence that Smad7-mediated apoptosis functionally
involves inhibition of NF-kB nuclear signalling (Lallemand et al,
2001; Schiffer et al, 2001) and in view of the present observations
that IkBa is upregulated within 6–24h, preceding the induction of
Smad7 (observed at 48h of treatment), one may suggest that
doxazosin may indeed have inhibitory effects on NF-kB signalling
pathway, by inducing IkBa, an action that subsequently triggers
apoptosis.
TIEG1 is an early TGF-b1 upregulated transcription factor that
has been documented to regulate apoptosis in several tumour cell
lines. The role of this nuclear factor has not yet been characterised
in prostate growth, but it might potentially involve the activation
of proapoptotic mechanisms, such as the downregulation of bcl-2
as reported in lung epithelial cells (Chalaux et al, 1999).
The a1-adrenoceptor antagonists doxazosin and terazosin share
structural similarities with particular TKIs owing to the presence
of a quinazoline ring (Figure 1). It is thus of major interest that
several quinazoline-based chemicals have been demonstrated to
compete with ATP binding to protein tyrosine kinases to inhibit
various intracellular signalling pathways (Rewcastle et al, 1995).
The mechanism of action for quinazoline-based TKI involves
prevention of the transmembrane tyrosine kinase phosphorylation
by competing with the ATP-binding site on the receptor (Arteaga
et al, 1997). The presence of this component may provide
additional valuable insights into the molecular mechanisms for
a1-adrenoceptor antagonist-mediated apoptotic action in tumour
cells (Anglin et al, 2002). Considering this evidence, one can
speculate on the potential function of the intrinsic quinazoline
component to confer partial TKI activity to these drugs, a unique
structural characteristic with potentially significant pharmacolo-
gical dimensions that warrant further investigation. Moreover, a
potential antiangiogenic effect of terazosin and doxazosin against
prostate tumours has been demonstrated in both in vitro and in
clinical prostate specimens (Chon et al, 1999; Keledjian et al, 2001;
Keledjian and Kyprianou, 2003). This action is believed to be
mediated by quinazoline-induced anoikis and inhibition of cell
invasion (Keledjian and Kyprianou, 2003).
In conclusion, we have demonstrated that doxazosin-mediated
apoptosis in prostate cancer cells involves activation of latent
apoptotic machinery via effectors of TGF-b1 signalling. In
addition, this initial molecular dissection revealed that an
inhibitory pathway involving NF-kB is triggered by this quinazo-
line-based a1-adrenoceptor antagonist. Several signalling mechan-
isms are likely to be involved in a molecular crosstalk, such as the
Smad activation and inhibition of the antiapoptotic effects of NF-
kB. Ongoing studies are focused on further characterisation of
these pathways and the functional significance of the over-
expressed genes in specimens from doxazosin-treated patients.
This will provide the molecular basis for assessing the potential
therapeutic significance of quinazoline monotherapy in androgen-
independent prostate cancer.
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